nach oben

Journal of General Internal Medicine

Erschienen in:

01.07.2010 | Original Article

Effect of Incarceration History on Outcomes of Primary Care Office-based Buprenorphine/Naloxone

verfasst von: Emily A. Wang, MD, MAS, Brent A. Moore, PhD, Lynn E. Sullivan, MD, David A. Fiellin, MD

Erschienen in: Journal of General Internal Medicine | Ausgabe 7/2010

Einloggen, um Zugang zu erhalten

Abstract

Background

Behaviors associated with opioid dependence often involve criminal activity, which can lead to incarceration. The impact of a history of incarceration on outcomes in primary care office-based buprenorphine/naloxone is not known.

Objective

The purpose of this study is to determine whether having a history of incarceration affects response to primary care office-based buprenorphine/naloxone treatment.

Design

In this post hoc secondary analysis of a randomized clinical trial, we compared demographic, clinical characteristics, and treatment outcomes among 166 participants receiving primary care office-based buprenorphine/naloxone treatment stratifying on history of incarceration.

Main Results

Participants with a history of incarceration have similar treatment outcomes with primary care office-based buprenorphine/naloxone than those without a history of incarceration (consecutive weeks of opioid-negative urine samples, 6.2 vs. 5.9, p = 0.43; treatment retention, 38% vs. 46%, p = 0.28).

Conclusions

Prior history of incarceration does not appear to impact primary care office-based treatment of opioid dependence with buprenorphine/naloxone. Community health care providers can be reassured that initiating buprenorphine/naloxone in opioid dependent individuals with a history of incarceration will have similar outcomes as those without this history.

Sabol WJ, Couture H. Prison and jail inmates at midyear 2007. Washington DC: US Department of Justice; 2008.

The PEW Center on the States. One in 31: the long reach of American corrections. In. Washington, DC; 2009.

Office of National Drug Control Policy. Drug Facts-Heroin. Executive Office of the President, ONDCP, 2007. (Accessed at http://www.whitehousedrugpolicy.gov/drugfact/heroin/index.html)

Rich JD, Boutwell AE, Shield DC, et al. Attitudes and practices regarding the use of methadone in US state and federal prisons. J Urban Health. 2005;82:411–419.PubMed

Nunn A, Zaller N, Dickman S, Trimbur C, Nijhawan A, Rich JD. Methadone and buprenorphine prescribing and referral practices in US prison systems: Results from a Nationwide Survey. Drug Alcohol Depend 2009

Mumola C, Karberg JC. Drug use and dependence, state and federal prisoners. 2006; Washgington DC.

Hanlon TE, Nurco DN, Kinlock TW, Duszynski KR. Trends in criminal activity and drug use over an addiction career. Am J Drug Alcohol Abuse. 1990;16:223–238.CrossRefPubMed

Morrow KM. HIV, STD, and hepatitis risk behaviors of young men before and after incarceration. AIDS care. 2009;21:235–243.CrossRefPubMed

Binswanger IA, Stern MF, Deyo RA, et al. Release from prison–a high risk of death for former inmates. N Engl J Med. 2007;356:157–165.CrossRefPubMed

10.

Gore SM, Bird AG, Burns SM, Goldberg DJ, Ross AJ, Macgregor J. Drug injection and HIV prevalence in inmates of Glenochil prison. BMJ. 1995;310:293–296.PubMed

11.

Chandler RK, Fletcher BW, Volkow ND. Treating drug abuse and addiction in the criminal justice system: improving public health and safety. JAMA. 2009;301:183–190.CrossRefPubMed

12.

Diversion and Abuse of Buprenoprhine: A Brief Assessment of Emerging Indicators. Center for Substance Abuse Treatment., 2006 (Accessed February 9, 2010, at http://buprenorphine.samhsa.gov/Buprenorphine_FinalReport_12.6.06.pdf.)

13.

Barry DT, Moore BA, Pantalon MV, et al. Patient satisfaction with primary care office-based buprenorphine/naloxone treatment. J Gen Intern Med. 2007;22:242–245.CrossRefPubMed

14.

Schwartz RP, Kelly SM, O’Grady KE, et al. Attitudes toward buprenorphine and methadone among opioid-dependent individuals. Am J Addict. 2008;17:396–401.CrossRefPubMed

15.

Travis J. But they all come back: facing the challenges of prisoner reentry. Washington, D.C.: Urban Institute; 2005.

16.

van Olphen J, Eliason MJ, Freudenberg N, Barnes M. Nowhere to go: how stigma limits the options of female drug users after release from jail. Subst Abuse Treat Prev Policy. 2009;4:10.CrossRefPubMed

17.

Schnittker J, John A. Enduring stigma: the long-term effects of incarceration on health. J Health Soc Behav. 2007;48:115–130.CrossRefPubMed

18.

Link BG, Struening EL, Rahav M, Phelan JC, Nuttbrock L. On stigma and its consequences: evidence from a longitudinal study of men with dual diagnoses of mental illness and substance abuse. J Health Soc Behav. 1997;38:177–190.CrossRefPubMed

19.

Cunningham CO, Kunins HV, Roose RJ, Elam RT, Sohler NL. Barriers to obtaining waivers to prescribe buprenorphine for opioid addiction treatment among HIV physicians. J Gen Intern Med. 2007;22:1325–1329.CrossRefPubMed

20.

Fiellin DA, Pantalon MV, Chawarski MC, et al. Counseling plus buprenorphine-naloxone maintenance therapy for opioid dependence. N Engl J Med. 2006;355:365–374.CrossRefPubMed

21.

American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Association; 1994.

22.

McLellan AT, Kushner H, Metzger D, et al. The fifth edition of the addiction severity index. J Subst Abuse Treat. 1992;9:199–213.CrossRefPubMed

23.

National Commission on Correctional Health Care ed. The health status of soon-to-be-released inmates: a report to congress I & II. 2002.

24.

McLellan TA, Zanis D, Incmikoski R, et al. Treatment Service Review (TSR). In: The Center for Studies in Addiction, Department of Psychiatry: Philadelphia VA Medical Center & The University of Pennsylvania; 1989

25.

French MT, Roebuck MC, McLellan AT, Sindelar JL. Can the treatment services review be used to estimate the costs of addiction and ancillary services? J Subst Abuse. 2000;12:341–361.CrossRefPubMed

26.

Hindelang MJ, Hiraschi T, Weis JG. Measuring delinquency. Thousand Oaks, CA: Sage Publications; 1981.

27.

Kosten TR, Rounsaville BJ, Kleber HD. Concurrent validity of the addiction severity index. J Nerv Ment Dis. 1983;171:606–610.CrossRefPubMed

28.

Cacciola JS, Alterman AI, Lynch KG, Martin JM, Beauchamp ML, McLellan AT. Initial reliability and validity studies of the revised treatment services review (TSR-6). Drug Alcohol Depend. 2008;92:37–47.CrossRefPubMed

29.

Makela K. Studies of the reliability and validity of the addiction severity index. Addiction. 2004;99:398–410. discussion 1–8.CrossRefPubMed

30.

Bovasso GB, Alterman AI, Cacciola JS, Cook TG. Predictive validity of the addiction severity index’s composite scores in the assessment of 2-year outcomes in a methadone maintenance population. Psychol Addict Behav. 2001;15:171–176.CrossRefPubMed

31.

Alterman AI, Cacciola JS, Habing B, Lynch KG. Addiction severity index recent and lifetime summary indexes based on nonparametric item response theory methods. Psychol Assess. 2007;19:119–132.CrossRefPubMed

32.

McDermott PAA, Arthur I, Brown L, Zaballero A, Snider EC, McKay JR. Construct refinement and confirmation for the addiction severity index. Psychol Assess. 1996;8:182–9.CrossRef

33.

Radloff L. The CES-D Scale: a self report depression scale for research in the general population. Appl Psychol Meas. 1977;1:385–401.CrossRef

34.

Knight K, Halcom M, Simpson D. TCU psychosocial functioning motivation scale: manual on psychometric properties. In: Institute for Behavioral Research; Texas Christian University; 1994.

35.

Rosenbaum PR, Rubin DB. Constructing a control group using multivariate matched sampling methods that incorporate the propensity score. Am Stat. 1985;39:33–38.CrossRef

36.

Gordon MS, Kinlock TW, Schwartz RP, O’Grady KE. A randomized clinical trial of methadone maintenance for prisoners: findings at 6 months post-release. Addiction. 2008;103:1333–1342.CrossRefPubMed

37.

Kinlock TW, Gordon MS, Schwartz RP, Fitzgerald TT, O’Grady KE. A randomized clinical trial of methadone maintenance for prisoners: results at 12 months postrelease. J Subst Abuse Treat. 2009;37:277–285.CrossRefPubMed

38.

Albizu-Garcia C, Caraballo-Correa G, Hernadez-Viver AD, et al. Buprenorphine-naloxone treatment of pre-release opioid-dependent inmates in Puerto Rico. J Addict Med. 2007;1:126–132.CrossRef

39.

Magura S, Lee JD, Hershberger J, et al. Buprenorphine and methadone maintenance in jail and post-release: a randomized clinical trial. Drug Alcohol Depend. 2009;99:222–230.CrossRefPubMed

40.

Becker WC, Fiellin DA, Merrill JO, et al. Opioid use disorder in the United States: insurance status and treatment access. Drug Alcohol Depend. 2008;94:207–213.CrossRefPubMed

41.

Jones ES, Moore BA, Sindelar JL, O’Connor PG, Schottenfeld RS, Fiellin DA. Cost analysis of clinic and office-based treatment of opioid dependence: results with methadone and buprenorphine in clinically stable patients. Drug Alcohol Depend. 2009;99:132–140.CrossRefPubMed

42.

Alterman AI, Bovasso GB, Cacciola JS, McDermott PA. A comparison of the predictive validity of four sets of baseline ASI summary indices. Psychol Addict Behav. 2001;15:159–162.CrossRefPubMed

43.

Thornberry TP, Krohn M. The self report method for measuring delinquency and crime. In: Measurement and Analysis of Crime and Justice. Washington DC: United States Department of Justice; 2000.

Titel: Effect of Incarceration History on Outcomes of Primary Care Office-based Buprenorphine/Naloxone
verfasst von: Emily A. Wang, MD, MAS
Brent A. Moore, PhD
Lynn E. Sullivan, MD
David A. Fiellin, MD
Publikationsdatum: 01.07.2010
Verlag: Springer-Verlag
Erschienen in: Journal of General Internal Medicine / Ausgabe 7/2010
Print ISSN: 0884-8734
Elektronische ISSN: 1525-1497
DOI: https://doi.org/10.1007/s11606-010-1306-0

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren.

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Proximale Humerusfraktur: Auch 100-Jährige operieren?

01.05.2024 DCK 2024 Kongressbericht

Mit dem demographischen Wandel versorgt auch die Chirurgie immer mehr betagte Menschen. Von Entwicklungen wie Fast-Track können auch ältere Menschen profitieren und bei proximaler Humerusfraktur können selbst manche 100-Jährige noch sicher operiert werden.

Die „Zehn Gebote“ des Endokarditis-Managements

30.04.2024 Endokarditis Leitlinie kompakt

Worauf kommt es beim Management von Personen mit infektiöser Endokarditis an? Eine Kardiologin und ein Kardiologe fassen die zehn wichtigsten Punkte der neuen ESC-Leitlinie zusammen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Background

Objective

Design

Main Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 7/2010

Factors Associated with Hepatitis B Testing Among Vietnamese Americans

Familial Risk of Cancer and Knowledge and Use of Genetic Testing

Patient Factors Associated with Guideline-concordant Treatment of Anxiety and Depression in Primary Care

An infinite fraction

Authors' Reply: Faculty Values

Interval Examination: The Ambulatory Long Block